Aeterna Zentaris Inc. and Hikma Pharmaceuticals PLC today announced their exclusive commercialization and licensing agreement to register and market perifosine, Aeterna Zentaris’ oral anti-cancer compound, in the Middle East and North Africa (MENA) region.
Perifosine is currently in two phase 3 programs for the treatment of colorectal cancer and multiple myeloma in the United States and Europe. Today’s news reflects perifosine’s market potential for cancer treatment on a global scale.
Juergen Engel, Ph.D., president and CEO of Aeterna Zentaris, noted Hikma’s position in the pharmaceutical market, as well as expectations for the collaborative agreement.
“Hikma Pharmaceuticals has a proven track record in oncology and is a leading drug company in the Middle East and North Africa region, which is why we believe it is a perfect fit for the development and commercialization of perifosine in that part of the world,” Dr. Engel stated in the press release. “Our partnership network for perifosine now encompasses North America, Japan, Korea and the MENA region, while we still retain all rights for the rest of the world. We look forward to the phase 3 results in colorectal cancer during the first quarter of 2012, as we continue our quest of bringing perifosine to the market worldwide for the benefit of both patients and shareholders.”
Per the agreement, Aeterna Zentaris will receive an upfront payment and additional payments of up to $2 million, contingent on the achievement of certain pre-established milestones. The deal calls for Aeterna Zentaris to supply perifosine to Hikma on a cost-plus-basis and is entitled to receive double-digit royalties on future net sales of perifosine in the MENA region; Hikma is responsible for the registration and commercialization of perifosine in the MENA territory.
Mazen Darwazah, vice chairman of Hikma, said the partnership gives Hikma access to a novel, oral anti-cancer treatment with high potential, complementing Hikma’s commitment to develop its own portfolio.
For more information visit www.aezsinc.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment